GeneDx Q4 Revenues Grow 6 Percent but Miss Consensus Estimate
The firm reiterated an earlier forecast of $205 million to $220 million in revenues for 2023, representing a slight decline over 2022.
In Brief This Week: Meridian Bioscience, BARDA, HHS, Oncocyte, GeneDx, More
News items for the week of Jan. 30, 2023.
GeneDx to Raise $150M in Public and Direct Stock Offerings
Expected to close Jan. 31, the stock sales are intended to help the firm build up working capital, repay debts, and make strategic investments.
Rebranded GeneDx Bets Future on Whole-Exome, Whole-Genome Sequencing in Pediatric Rare Disease
After dropping underdeveloped Sema4 business lines but emphasizing the Centrellis informatics platform, the new GeneDx expects to reach profitability by 2025.
Sema4 Changes Name to GeneDx, Provides Preliminary 2022 Revenues, 2023 Guidance
As it exits reproductive health screening this quarter, the newly renamed GeneDx expects 2022 revenues of $170 million to $173 million and 2023 revenues of $205 million to $220 million in pursuit of profitability by 2025.